X4 Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapies for immune system dysregulation disorders. The primary focus of X4 Pharmaceuticals is to research and develop small molecule therapeutics that target rare diseases with limited treatment options. Their flagship product candidates often aim to modulate the CXCR4 chemokine receptor, which plays a crucial role in immune cell trafficking and development. X4 Pharmaceuticals’ pipeline spans a range of clinical stages, focusing on conditions such as WHIM syndrome, severe congenital neutropenia, and chronic neutropenia. The company's work primarily impacts the healthcare and biotechnology sectors, particularly in specialty pharmaceuticals where treatment innovation is highly needed. Headquartered in Boston, Massachusetts, X4 Pharmaceuticals continues to collaborate with research institutions and healthcare practitioners to advance its drug candidates through clinical trials and regulatory pathways. The company’s efforts contribute significantly to the development of targeted treatments that address unmet medical needs in rare disease communities, thus playing a pivotal role in advancing healthcare outcomes.